Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Mims

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Blood|August 13, 2011
Epigenetic priming: the target?Alice Mims, Guido Marcucci
Current Opinion in Hematology|January 7, 2020
Relapsed or primary refractory AML: moving past MEC and FLAG-idaKristin Koenig, Alice Mims
Current Hematologic Malignancy Reports|May 4, 2013
Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?Alice Mims, Robert K Stuart
Molecular Pharmacology|January 26, 2006
Merbarone induces activation of caspase-activated DNase and excision of chromosomal DNA loops from the nuclear matrixYoko Otake, Alice Mims, Daniel J Fernandes
Journal of Geriatric Oncology|January 22, 2019
Geriatric Hematology Research presented at the 2018 American Society of Hematology Annual Meeting: Young International Society of Geriatric Oncology Perspective PaperKah Poh Loh, Konstantinos Christofyllakis, Li-Wen Huang, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 3, 2020
The Changing Landscape of Treatment in Acute Myeloid LeukemiaKristin Koenig, Alice Mims, Mark J Levis, et al.
Frontiers in Oncology|October 20, 2022
Survival, response rates, and post-transplant outcomes in patients with Acute Myeloid Leukemia aged 60-75 treated with high intensity chemotherapy vs. lower intensity targeted therapyKieran Sahasrabudhe, Ying Huang, Melanie Rebechi, et al.
Cancer Medicine|April 15, 2018
Incidence and survival of hematological cancers among adults ages ≥75 yearsJessica L Krok-Schoen, James L Fisher, Julie A Stephens, et al.
Leukemia & Lymphoma|November 28, 2024
Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemiaAlice Mims, Zhuoer Xie, Ravi Potluri, et al.
Leukemia & Lymphoma|October 12, 2024
Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapiesJean Caputo, Ayush Peddireddi, Subodh Bhatta, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Blood|August 13, 2011
Epigenetic priming: the target?Alice Mims, Guido Marcucci
Current Opinion in Hematology|January 7, 2020
Relapsed or primary refractory AML: moving past MEC and FLAG-idaKristin Koenig, Alice Mims
Current Hematologic Malignancy Reports|May 4, 2013
Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?Alice Mims, Robert K Stuart
Molecular Pharmacology|January 26, 2006
Merbarone induces activation of caspase-activated DNase and excision of chromosomal DNA loops from the nuclear matrixYoko Otake, Alice Mims, Daniel J Fernandes
Journal of Geriatric Oncology|January 22, 2019
Geriatric Hematology Research presented at the 2018 American Society of Hematology Annual Meeting: Young International Society of Geriatric Oncology Perspective PaperKah Poh Loh, Konstantinos Christofyllakis, Li-Wen Huang, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 3, 2020
The Changing Landscape of Treatment in Acute Myeloid LeukemiaKristin Koenig, Alice Mims, Mark J Levis, et al.
Frontiers in Oncology|October 20, 2022
Survival, response rates, and post-transplant outcomes in patients with Acute Myeloid Leukemia aged 60-75 treated with high intensity chemotherapy vs. lower intensity targeted therapyKieran Sahasrabudhe, Ying Huang, Melanie Rebechi, et al.
Cancer Medicine|April 15, 2018
Incidence and survival of hematological cancers among adults ages ≥75 yearsJessica L Krok-Schoen, James L Fisher, Julie A Stephens, et al.
Leukemia & Lymphoma|November 28, 2024
Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemiaAlice Mims, Zhuoer Xie, Ravi Potluri, et al.
Leukemia & Lymphoma|October 12, 2024
Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapiesJean Caputo, Ayush Peddireddi, Subodh Bhatta, et al.
Pageof 5